Bayer: Carcinoma, Hepatocellular trials
The registry lists 34 Carcinoma, Hepatocellular studies with Bayer as lead sponsor. 1 are open to participants now and 12 have results posted.
Phase 1 4Phase 2 9Phase 3 6Phase 4 1No phase 14(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver CancerRecruitingNCT06764316Phase 1
- Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted
- A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been CompletedCompletedNCT03890731Phase 2Results posted
- Study of Regorafenib After Sorafenib in Patients With Hepatocellular CarcinomaCompletedNCT01774344Phase 3Results posted
- Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.CompletedNCT01043523Results posted
- Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular CarcinomaCompletedNCT00901901Phase 3Results posted
- A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).CompletedNCT00855218Phase 2Results posted
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)CompletedNCT00692770Phase 3Results posted
- Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)CompletedNCT00494299Phase 3Results posted
- A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00492752Phase 3Results posted
- A Research Study to Treat Patients With Advanced Hepatocellular CarcinomaCompletedNCT00108953Phase 2Results posted
- A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00105443Phase 3Results posted
- A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular CarcinomaCompletedNCT00044512Phase 2Results posted
- A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid CancersCompletedNCT06345001Phase 1
- An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With SurgeryActive, not recruitingNCT06117891
- An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
- Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line TreatmentTerminatedNCT03644511
- Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
- Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by SorafenibCompletedNCT01933945
- Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)CompletedNCT01915602Phase 2
- Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)CompletedNCT01915589Phase 2
- Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and SafetyCompletedNCT01908322
- Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in ChinaCompletedNCT01839630
- Sorafenib for Residue Disease After Resection With Curative IntentCompletedNCT01751763
- Sorafenib in Hepatocellular Carcinoma Clinical Practice in ItalyCompletedNCT01539681
- Hepatocellular Carcinoma Registry for Turkey (3K Trial)CompletedNCT01473121
- Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in JapanCompletedNCT01411436
- Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.CompletedNCT01204177Phase 2
- GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study StartWithdrawnNCT01191385
- Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese PatientsCompletedNCT01098760Phase 4
- Regulatory Post Marketing Surveillance Study on Nexavar®CompletedNCT01012011
- Safety Study of BAY73-4506 in Patients With Hepatocellular CarcinomaCompletedNCT01003015Phase 2
- Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With SorafenibCompletedNCT00812175
- INSIGHT - Post Marketing SurveillanceCompletedNCT00792350